BioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024. In the quarter to June 2026, revenue grew 33.6%, EPS grew 1,450.0%, free cash flow grew 153.2% and total debt rose 15.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow BCRX
BioCryst Pharmaceuticals, Inc. (BCRX) EV/Sales
As of 16 October 2026, BioCryst Pharmaceuticals, Inc. (BCRX) trades at a EV/Sales of 2.6×. Over the past ten years it has ranged from 1.5× (February 2016) to 127× (March 2021); the current reading is higher than 3% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.1× | (53.99%) |
| FY2024 | 4.6× | (5.94%) |
| FY2023 | 4.9× | (45.97%) |
| FY2022 | 9.0× | (44.75%) |
| FY2021 | 16.3× | (76.25%) |
| FY2020 | 68.7× | 965.34% |
| FY2019 | 6.4× | (82.47%) |
| FY2018 | 36.8× | 151.84% |
| FY2017 | 14.6× | (12.16%) |
| FY2016 | 16.6× | 14.33% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.2× | (2.49%) |
| Mar 2026 | 3.3× | 56.86% |
| Dec 2025 | 2.1× | (38.50%) |
| Sep 2025 | 3.4× | (18.57%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −0.1× |
| PRGO Perrigo Company plc compare | 1.3× |
| PAHC Phibro Animal Health Corporation compare | 1.5× |
| ANIP ANI Pharmaceuticals, Inc. compare | 1.8× |
| BCRX BioCryst Pharmaceuticals, Inc. | 2.6× |
| SUPN Supernus Pharmaceuticals, Inc. compare | 2.8× |
| PBH Prestige Consumer Healthcare Inc. compare | 3.9× |
| XERS Xeris Biopharma Holdings, Inc. compare | 5.7× |
| ALVO Alvotech compare | 9.0× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)